Replay next-generation gene therapy for DEB
| Biotech website | replay.bio |
| Investment details | $100,000 (£76,170) |
| Start date | September 2025 |
| Research area | Gene therapy |
| EB sub-type | Dystrophic EB |
| Aim | Quality of life change |
| Investment status | Current |
Investment summary
Replay is advancing a next-generation gene therapy platform designed for RDEB. The platform uses an engineered herpes simplex virus (HSV) vector to deliver the COL7A1 gene, which encodes for Type VII collagen. The platform has shown promise in preclinical models.